Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2031210011
JPRN-jRCT2031210011
Active, not recruiting
Phase 2

A phase II study to evaluate the efficacy and safety of M605106 short contact therapy in patients with acne vulgaris

ishiura Tomoyuki0 sites240 target enrollmentApril 5, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
ishiura Tomoyuki
Enrollment
240
Status
Active, not recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 5, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
ishiura Tomoyuki

Eligibility Criteria

Inclusion Criteria

  • •Patients with Acne vulgaris 12 to 49 years old

Exclusion Criteria

  • •\- Patients with concurrent presense of serious cardiac, hepatic, renal, plumonary, hematologic, or other diseases considered inappropriate for paticipation in the clinical study
  • •\- Patients with a history of hypersensitivity to investigational drug ingredients
  • •\- Pregnant or lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
A Phase II stUdy to evaluate the efficacy and safety of deep-inspiration breath-hold Daily aDaptive radiotherapy In ceNtrally located lunG tumorsPrimary lung tumorLung cancerMetastatic lung tumorPulmonary metastasisOligometastasisD008175
JPRN-jRCT1052230085Takashi Mizowaki25
Active, not recruiting
Phase 1
Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.Crohn's DiseaseMedDRA version: 19.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2012-004098-26-DEAstraZeneca AB120
Active, not recruiting
Phase 1
Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.Crohn's DiseaseMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2012-004098-26-CZAstraZeneca AB120
Active, not recruiting
Phase 1
Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.Crohn's DiseaseMedDRA version: 18.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2012-004098-26-FRAstraZeneca AB121
Active, not recruiting
Phase 1
Evaluation of efficacy and safety of MEDI2070 in patients with active,moderate-to-severe Crohn's disease.
EUCTR2012-004098-26-ITASTRAZENECA120